Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verve Therapeutics, Inc. - Common Stock (NQ:VERV)

11.13 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Verve Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
3 Bullish Biotech Stocks With Explosive Growth Trends
These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies 
Via MarketBeat
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO. 
Via MarketBeat
Topics Economy Stocks
VERVE THERAPEUTICS INC (NASDAQ:VERV) - A High-Growth Biotech Stock Meeting Minervini's Criteria
VERVE THERAPEUTICS (VERV) is a high-growth biotech stock meeting Minervini's Trend Template criteria, with strong revenue growth, bullish technicals, and upward earnings revisions. 
Via Chartmill
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Via The Motley Fool
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate. 
Via Benzinga
This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
 
Via Benzinga
Market Monitor News June 18 (Jabil, Reddit & Verve Therapeutics UP - Solar Stocks First Solar, Sunrun & SolarEdge DOWN)
Wall Street stays cool despite geopolitical tension, weak retail data, and a meltdown in solar stocks. 
Via Chartmill
5 Analysts Assess Verve Therapeutics: What You Need To Know
 
Via Benzinga
These stocks are moving in today's session
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Which stocks are moving on Tuesday?
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
Why Verve Therapeutics Stock Is Skyrocketing Today
Via The Motley Fool
Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Which stocks are gapping on Tuesday?
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
Verve Therapeutics Stock Rockets 75% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B: Retail Says Offer Is ‘Low’
Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share,... 
Via Stocktwits
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments. 
Via Investor's Business Daily
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
 
Via Benzinga
Get insights into the top gainers and losers of Tuesday's pre-market session.
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition
Eli Lilly is acquiring Verve Therapeutics to strengthen its cardiovascular pipeline with a gene-editing drug targeting PCSK9-linked conditions. 
Via Benzinga
Why Lennar Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Verve Therapeutics Soars 75% After-Hours Following Report Of $1.3B Eli Lilly Takeover Talks
The deal would double Verve’s market value and expand Lilly’s pipeline of early-stage therapies. 
Via Stocktwits
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst
CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025. 
Via Benzinga
1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street
Via The Motley Fool
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Why Verve Therapeutics Zoomed 40% Higher This Week
Via The Motley Fool
Topics Intellectual Property
Unusual volume stocks are being observed in Tuesday's session.
Let's have a look at the stocks with an unusual volume in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why Verve Therapeutics Is Skyrocketing Today
Via The Motley Fool
The market is filled with gapping stocks in Tuesday's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.